Related Experiment Video
Updated: Aug 6, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Advances in cancer vaccines for immunotherapy of prostate cancer
Tongtong Jin1, Chuan Zhou2, Lei Zhao3
1First School of Clinical Medicine, Lanzhou University, Lanzhou 730000. Jinttlzu@163.com.
Abstract:
Prostate cancer is currently one of the most common malignancies that endanger the lives and health of elderly men. In recent years, immunotherapy, which exploits the activation of anti-cancer host immune cells to accomplish tumor-killing effects, has emerged as a new study avenue in the treatment of prostate cancer. As an important component of immunotherapy, cancer vaccines have a unique position in the precision treatment of malignant tumors. Monocyte cell vaccines, dendritic cell vaccines, viral vaccines, peptide vaccines, and DNA/mRNA vaccines are the most often used prostate cancer vaccines. Among them, Sipuleucel-T, as a monocyte cell-based cancer vaccine, is the only FDA-approved therapeutic vaccine for prostate cancer, and has a unique position and role in advancing the development of immunotherapy for prostate cancer. However, due to its own limitations, Sipuleucel-T has not been widely adopted. Meanwhile, owing to the complexity of immunotherapy and the specificity of prostate cancer, the remaining prostate cancer vaccines have not shown good clinical benefit in large randomized phase II and phase III trials, and further in-depth studies are still needed.
Insights
Prostate cancer immunotherapy, particularly cancer vaccines, shows promise but faces challenges. Sipuleucel-T is the only FDA-approved option, yet limitations and the complexity of prostate cancer hinder widespread clinical benefit from current vaccines.
Area of Science:
- Oncology
- Immunology
- Vaccinology
Background:
- Prostate cancer is a leading cause of mortality in elderly men.
- Immunotherapy, especially cancer vaccines, is a promising approach for prostate cancer treatment.
- Various vaccine types, including Sipuleucel-T, are explored for their therapeutic potential.
Purpose of the Study:
- To review the landscape of prostate cancer vaccines within immunotherapy.
- To highlight the significance and limitations of Sipuleucel-T.
- To assess the clinical benefits and future research needs for prostate cancer vaccines.
Main Methods:
- Review of existing literature on prostate cancer immunotherapy and vaccines.
- Analysis of clinical trial outcomes for different vaccine types.
- Discussion of Sipuleucel-T's approval, role, and limitations.
Main Results:
- Sipuleucel-T is the sole FDA-approved therapeutic vaccine for prostate cancer.
- Despite its unique position, Sipuleucel-T faces adoption challenges due to inherent limitations.
- Other prostate cancer vaccines have not demonstrated significant clinical benefits in large trials.
Conclusions:
- Prostate cancer immunotherapy, particularly via vaccines, requires further research and development.
- Overcoming limitations of current vaccines and addressing prostate cancer's complexity are crucial for clinical success.
- In-depth studies are necessary to improve the efficacy of cancer vaccines in treating prostate cancer.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...